GlassScriptPhysician profile
Diane M Burt
NPI 1043229883
$81,248.07
in general payments reported to CMS, 2019-2025
29 companies · $6,739 in 2025
The $6,739 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21K · 2022: $21K · 2023: $22K · 2024: $11K · 2025: $6,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Food and Beverage: $6,212 · Travel and Lodging: $1,301 · Education: $18.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,762.50 |
| Food and Beverage | $6,211.89 |
| Travel and Lodging | $1,300.80 |
| Education | $18.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $72,267.25 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,550.75 | 2021-2025 | Caplyta |
| Allergan, INC. | $1,100.00 | 2021 | |
| Axsome Therapeutics, INC. | $797.84 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $786.91 | 2021-2025 | Rexulti, Nuedexta, Abilify Mycite |
| Alkermes, INC. | $595.39 | 2021-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $564.40 | 2021-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $477.60 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $459.28 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $380.90 | 2021-2024 | Trintellix |
| Tris Pharma INC | $272.50 | 2021-2024 | Dyanavel Xr |
| Bausch Health US, LLC | $266.02 | 2021-2024 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $262.06 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $224.57 | 2021-2024 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $205.05 | 2022-2023 | Fanapt, Hetlioz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $163.73 | 2021-2022 | |
| Corium, LLC | $157.97 | 2022-2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $131.81 | 2021-2022 | |
| Noven Therapeutics, LLC | $98.79 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $95.63 | 2021-2023 | Belsomra |
| Almatica Pharma LLC | $95.44 | 2023-2024 | Loreev Xr, Gralise |
| Ironshore Pharmaceuticals INC. | $80.70 | 2023-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $69.32 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.53 | 2024 | Invega, Spravato |
| Sage Therapeutics, LLC | $28.74 | 2024 | |
| Uswm, LLC | $27.68 | 2021 | |
| Eisai INC. | $26.66 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.88 | 2021 | |
| Owp Pharmaceuticals, INC. | $15.67 | 2023 | Subvenite, Lamotrigine |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Burt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.